Drugs / Hepabig
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05686759 | Apr 2023 → Jun 2026 overdue | hepatitis B virus infection | GC Biopharma Corp | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hepabig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05686759 ↗ |
| Known as | GC5103 | “undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit” NCT05686759 ↗ |
| Route | Intravenous | “Undiluted intravenous infusion of I.V.-Hepabig inj” NCT05686759 ↗ |